<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803475</url>
  </required_header>
  <id_info>
    <org_study_id>185513</org_study_id>
    <secondary_id>NCI-2019-01394</secondary_id>
    <nct_id>NCT03803475</nct_id>
  </id_info>
  <brief_title>Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients</brief_title>
  <official_title>Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Hope</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are imaging patients with prostate cancer using a new Positron Emission
      Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect
      prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of
      metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on
      prostate cancer cells that can be imaged using small molecules that target this protocol. PET
      imaging will begin 50-100 minutes after injection, but may be possible in certain
      circumstances for imaging to be delayed due to patient workflow or equipment issues

      Primary Objective:

      Sensitivity on a per-patient and per-region-basis (Table 1) of 68Ga-PSMA-11 PET for detection
      of tumor location confirmed by histopathology/biopsy, clinical and conventional imaging
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">July 22, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate stratified by prostate-specific antigen (PSA) level</measure>
    <time_frame>1 day</time_frame>
    <description>Based on local reads for the detection of metastatic disease, the rate of localization abnormal focus of radiotracer will be stratified based upon the PSA prior to imaging</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ga-68 labeled PSMA-11 PET PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 mCi +/- 10% of 68Ga-PSMA-11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 labeled PSMA-11</intervention_name>
    <description>Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
    <arm_group_label>Ga-68 labeled PSMA-11 PET PSMA</arm_group_label>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED- CC</other_name>
    <other_name>Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled HBED-CC PSMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron emission tomography-computed tomography (PET/CT)</intervention_name>
    <description>Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session</description>
    <arm_group_label>Ga-68 labeled PSMA-11 PET PSMA</arm_group_label>
    <other_name>PET-CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron emission tomography-magnetic resonance imaging (PET/MRI)</intervention_name>
    <description>A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session</description>
    <arm_group_label>Ga-68 labeled PSMA-11 PET PSMA</arm_group_label>
    <other_name>PET-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, age â‰¥ 18.

          2. Histopathologically proven prostate adenocarcinoma.

          3. Concern for metastatic disease in one of the following settings:

               1. Initial staging with intermediate to high risk prostate cancer.

               2. Biochemical recurrence after initial therapy.

          4. Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria:

        1. Patient unlikely to comply with study procedures, restrictions and requirements and
        judged by the Investigator to be unsuitable for study participation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

